Educational Qualifications: MSc, Ph.D. (Biochemistry)

Dr. Gupta is a technopreneur in the niche domain of preventive healthcare committed to promote advanced technologies in cancer diagnostics. A molecular biochemist by training Dr. Gupta is engaged in early detection and prevention of cervical cancer for nearly two decades. He was associated with Digene/Qiagen, USA and later, with IncellDx, USA as clinical consultant, largely mentoring clinical adoption of molecular HPV DNA, HPV genotyping, Liquid Cytology and HPV E6, E7 mRNA technologies in India.

Dr. Gupta played a key role in supporting the Melinda & Gates Foundation sponsored multicentric randomized clinical studies (RCTs) on the prevalence of oncogenic HPV and CIN precursor lesions in India, conducted by IARC/WHO mainly at Tata Memorial Hospital, Mumbai; CNCI, Kolkata; Regional Cancer Centres covering over hundred thousand women in India. He assisted over 50 leading corporate and public laboratories in India, Bangladesh, Nepal, Pakistan and UAE in adopting molecular HPV technologies and colposcopy training sessions through CMEs, clinical seminars and RTMs.

Dr. Gupta headed CureHealth Diagnostics reference laboratory and was also a consulting expert for SRL Diagnostics on HPV and cervical screening program. He is closely associated with the key opinion leaders in the field of gynecological oncology.

He was also an honorary medical specialist (2015-16) at for Thane Municipal Corporation, Thane, Mumbai. He instituted a cervical cancer screening and prevention program at Thane to screen the largest ever population in India covering half a million women in a span of 5 years.

Dr. Gupta, in his professional capacity, is a Life Member of various cancer research organizations such as Indian Association for Cancer Research (IACR), Indian Society for Colposcopy & Cervical Pathology (ISCCP); Asia-Oceania Research Organization on Genital Infections and Neoplasia (AOGIN); Association of Gynaecological Oncologists of India (AGOI); Indian Menopause Society (IMS); Molecular Pathology Association of India (MPAI).

Basic research interest in the Predictive Efficacy of Radiation Response On Survival Outcomes For Patients Treated With Brachytherapy.

Recent Publications:

• Comparison of LBC, HPV DNA and HPV E6/E7 mRNA in Routine Clinical Practice: Our Intermediate Study Data at the Tertiary Care Hospital. AOGIN 2015, CMC Vellore.
• HPV Confers Radiosensitivity in Cancer Cervix. Future Oncology 2015, 11(9).
• Periodontal Pocket as a Potential Reservoir of High-Risk Human Papillomavirus: A pilot study. Ind Soc of Periodontology, Published by Wolters Kluwer – Medknow 2015
• Does The Quantum of Local Tumour HPV Positivity in Cervix Cancers Lead to a Radiobiologically Different Tumour Cell Population? Asia-Pac J Clin Oncol (2013)
• Does Pretreatment Human Papillomavirus (HPV) Titers Predict Radiation Response And Survival Outcomes in Cancer Cervix?—A Pilot Study. Gynaecologic Oncology (2006)

Apart from above, published a number of review articles in national ObGyn, ISCCP and FOGSI journals/ newsletters.